Results 181 to 190 of about 58,391 (264)

Association between CD56, CD38 and chronic endometritis and analysis of pregnancy prognosis: a single-center retrospective cohort study. [PDF]

Front Med (Lausanne)
Kong Y, Zhou S, Zhou Q.
europepmc   +1 more source

Metabolic Regulation of Macrophages in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang, Yu Zhang, Jiali Min, Jiahui Yang, Yuchen Li, Hao Zhang, Shanshan Liu   +6 more
wiley   +1 more source

Regulating the regulators via targeting CD38 in the tumor microenvironment. [PDF]

Front Immunol
Dutta N, Halder N, Chini EN, Kim S, Manna A.   +4 more
europepmc   +1 more source

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
Inflammation in cardiovascular disease is a dynamic and context‐dependent network rather than a secondary response to injury. Mitochondrial danger signaling links metabolic stress to immune activation through TLR priming, NLRP3 inflammasome amplification, cGAS–STING signaling, and immunometabolic gating, providing a basis for more precise therapeutic ...
Jiaxiang Rong, Zhen Wang, Xiaoxiao Lin, Ziwen Lei, Qianqian Huang, Hang Liu, Fei Luan, Junbo Zou, Yajun Shi   +8 more
wiley   +1 more source

Novel Roles for the Ectoenzyme CD38 in the Maintenance of Transcriptional and Metabolic Homeostasis in Astrocytes. [PDF]

Glia
Basak S, Colafrancesco AM, Hernandez RD, Wei X, McMeekin LJ, Dang D, Simmons M, Browning JL, Noel K, Zhou F, Lund FE, Saad JS, Watsen SG, Pickrell AM, Cowell RM, Olsen ML.   +15 more
europepmc   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8⁺T cell-mediated anti-tumor immunity. [PDF]

Nat Commun
Liang L, Li W, Liu S, He Q, Zeng F, Cao J, Lei Y, Li Y, Zhou Y.   +8 more
europepmc   +1 more source

The Divergent Effects of Nicotinamide Riboside and High‐Intensity Exercise Training on Skeletal Muscle Epigenetic Aging

Aging Cell, Volume 25, Issue 8, August 2026.
This study investigated the effects of nicotinamide riboside supplementation and high‐intensity interval training on skeletal muscle epigenetic aging. Our findings reveal that both interventions may modify epigenetic aging, with the muscle‐specific MEAT and DunedinPACE clocks showing the most responsiveness and links to mitochondrial abundance ...
Aino Heikkinen, Liina Uusitalo‐Kylmälä, Ida Blom, Jørn Wulff Helge, Linn Gillberg, Robert Seaborne, Steen Larsen, Macsue Jacques, Robin Grolaux, Sari Aaltonen, Jaakko Kaprio, Birgitta W. van der Kolk, Sini Heinonen, Nir Eynon, Kirsi H. Pietiläinen, Riikka Kivelä, Eija Pirinen, Miina Ollikainen   +17 more
wiley   +1 more source

High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. [PDF]

Curr Oncol
Awadallah C, Zayad A, Atrash S, Mazloom A, Alkharabsheh O, Mewawalla P, Shah MR, Lutfi F, Mahmoudjafari Z, Umair Mushtaq M, Kort J, Habib A, Abdallah AO.   +12 more
europepmc   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 573-583, August 2026.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source